ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter

Dow Jones

2025/12/25

By Nicholas G. Miller

ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration.

The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays.

It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities.

ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer.

The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

December 24, 2025 13:40 ET (18:40 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2594409967"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594409967\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594409967?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-25 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594409967","market":"sh","top_or_hot":-1,"title":"ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n</p>\n<p>\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n</p>\n<p>\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n</p>\n<p>\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n</p>\n<p>\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 13:40 ET (18:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-25 02:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n</p>\n<p>\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n</p>\n<p>\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n</p>\n<p>\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n</p>\n<p>\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 13:40 ET (18:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCC","symbol_name":"伊芙美爾醫療","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594409967","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594409967","pubTimestamp":1766601600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration.The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays.It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities.ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer.The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a re","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCC":"伊芙美尔医疗","BK4139":"生物科技"},"translate_title":"ImmuCell在收到FDA不完整信函后暂停投资奶牛乳腺炎药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCC":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n\n\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n\n\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n\n\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n\n\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2025 13:40 ET (18:40 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}